415-130-7 | Sigma-Aldrich

XP725 Antibody Number-Lot Number 071M4826

384 5.1 385 386 387 388 409 410 411 412 433 434 435 436 457 458 459 460 5.2 389 390 391 392 413 414 415 416 437 438 439 440 461 462 463 464 5.3 393 394 395 396 417 418 419

Data Sheet: Fractogel® Chromatography Resin

EMD SO3 resin After equilibration (25 mM Sodium Phosphate buffer, pH 5.5) the sample containing 415 mg of protein (corresponding to 30 mg mAb) was loaded onto the column. Subsequently, the column was

PKH Dye Reference Guide

lifetime 94, 150, 200, 207, 208 Proliferation, growth control 29, 126, 130 Differentiation, embryogenesis 4, 9, 29, 87, 126, 130, 148 Adhesion 69, 46, 196 Blood flow assessment 68

Apoptosis - Antibodies, Reagents and Kits

40 assays S7110 $405 ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit 40 assays S7111 $415 ApopTag Red In Situ Apoptosis Detection Kit 40 assays S7165 $390 Other Apoptosis Detection Products

Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease

adenoma using the technique of expression cloning [4]. The protein was characterized as containing 415 amino acid residues with seven putative transmem- brane domains and five potential extracellular N-

In vitro generated extracellular matrix and fluid shear stress synergistically enhance 3D osteoblastic differentiation

Frayssinet, P., Rtaimate, M., Hildebrand, H. F. & Marchandise, X. (2000) J. Biomed. Mater. Res. 49, 415–421. 45. Yuan, H., Zou, P., Yang, Z., Zhang, X., De Bruijn, J. D. & De Groot, K. (1998) J. Mater

Cytoskeletal Signaling Antibodies, Reagents and Kits

Integrin Molecular Weights (kDa) by SDS-PAGE MW (kDa) Reduced Conditions 210 165 130 150 135 120 125 120 130 95 105 220 110 MW (kDa) Non-Reduced Conditions 200 160 150 140 155 140 150 145 110

XP725 Antibody List Lot 129K4831

3952 LEP P NP_000221.1 y y n/d 409 LIM Kinase 1 L2290 3984 LIMK1 P NP_001191355.1,NP_002305.1 y y y 415 Mad2 M8694 4085 MAD2L1 M NP_002349.1 y n/d n/d 677 Smad4 (DPC4) S3934 4089 SMAD4 M NP_005350.1 y n/

XP725 Antibody List Lot 129K4830

3952 LEP P NP_000221.1 y y n/d 409 LIM Kinase 1 L2290 3984 LIMK1 P NP_001191355.1,NP_002305.1 y y y 415 Mad2 M8694 4085 MAD2L1 M NP_002349.1 y n/d n/d 677 Smad4 (DPC4) S3934 4089 SMAD4 M NP_005350.1 y n/

XP725 Antibody List Lot 089K4791

3952 LEP P NP_000221.1 y y n/d 409 LIM Kinase 1 L2290 3984 LIMK1 P NP_001191355.1,NP_002305.1 y y y 415 Mad2 M8694 4085 MAD2L1 M NP_002349.1 y n/d n/d 677 Smad4 (DPC4) S3934 4089 SMAD4 M NP_005350.1 y n/

XP725 Worksheet for Lot Number 071M4826

4 Cytokeratin 8 12 C7034 413 3 1 4 5 Cytokeratin 8 13 C6909 414 3 1 4 6 Cytokeratin 8 13 C6909 415 3 1 4 7 Cytokeratin peptide 13 C0791 416 3 1 4 8 Cytokeratin peptide 13 C0791 417 3 1 5

List of Antibodies

NA 409 LIM Kinase 1 L2290 P y y y 410 LIN-7 L1538 P n/d n/d y 411 LIS1 L7391 M y y y 412 LKB1 L7917 P y y y 413 LDS1 L4793 P y y y 414 Mad1 M8069 M y n/d n/d 415 Mad2

Biodiscover Whole Genome Amplification Advisor

Resistance to EGFR Inhibitors and the Development of Brain Metastasis Am. J. Pathol., Jul 2010; 177: 415 - 423. Raisa Vuononvirta, Neil J. Sebire, Anthony R. Dallosso, Jorge S. Reis-Filho, Richard D. Williams

XP725 Antibody List

23028 Aof2,AOF2 NP_598633.1,NP_055828.2 P y y y 414 Mad1 M8069 8379 MAD1L1 NP_003541.2 M y n/d n/d 415 Mad2 M8694 4085 MAD2L1 NP_002349.1 M y n/d n/d 416 MADD M5683 94193, 228355, 8567 Madd,MADD NP_446037.1

XP725 Antibody List 013M4793

23028 Aof2,AOF2 NP_598633.1,NP_055828.2 P y y y 414 Mad1 M8069 8379 MAD1L1 NP_003541.2 M y n/d n/d 415 Mad2 M8694 4085 MAD2L1 NP_002349.1 M y n/d n/d http://www.sigmaaldrich.com/ProductLookup.html

Halal Certificate

W333200 C10282 HC-23SIO948 414. BUTAN-3-ONE-2-YL BUTANOATE 98%, FCC W333204 B38138 HC-23SI7X05 415. BUTYL (S)-(-)-LACTATE 97% W220507 B69484 HC-23SI5K29 416. BUTYL (S)-(-)-LACTATE, 97%, FG W220500

Halal Certificate

W333200 C10282 HC-22SI9B69 414. BUTAN-3-ONE-2-YL BUTANOATE 98%, FCC W333204 B38138 HC-22SIDX26 415. BUTYL (S)-(-)-LACTATE 97% W220507 B69484 HC-22SIEQ50 416. BUTYL (S)-(-)-LACTATE, 97%, FG W220500